Pamrevlumab
Pamrevlumab (also known as FG-3019) is an experimental drug developed by FibroGen for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. It is a human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic diseases and cancer.
Mechanism of Action[edit]
Pamrevlumab works by binding to and inhibiting the activity of CTGF, a protein that is overexpressed in many fibrotic diseases and cancers. By blocking the activity of CTGF, pamrevlumab can potentially slow down or halt the progression of these diseases.
Clinical Trials[edit]
Pamrevlumab has undergone several clinical trials for different indications. In a Phase 2 trial for idiopathic pulmonary fibrosis, the drug showed a significant reduction in disease progression compared to placebo. It is currently in Phase 3 trials for this indication.
For pancreatic cancer, pamrevlumab has shown promise in combination with gemcitabine and nab-paclitaxel in a Phase 2 trial. The drug is also in Phase 2 trials for Duchenne muscular dystrophy.
Potential Side Effects[edit]
As with any drug, pamrevlumab may cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. However, the severity and frequency of these side effects can vary among individuals.
See Also[edit]
- FibroGen
- Idiopathic pulmonary fibrosis
- Pancreatic cancer
- Duchenne muscular dystrophy
- Connective tissue growth factor
- Clinical trial
 | This medical article is a stub. You can help WikiMD by expanding the page. |
| This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
